Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,144
archived clinical trials in
Ocular

Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)
A Multicenter, Randomized, Sham-control, Proof-of-concept Study of Intravitreal LFG316 in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Sacramento, CA
Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)
A Multicenter, Randomized, Sham-control, Proof-of-concept Study of Intravitreal LFG316 in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Sacramento, CA
Click here to add this to my saved trials
Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)
A Multicenter, Randomized, Sham-control, Proof-of-concept Study of Intravitreal LFG316 in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Colorado Springs, CO
Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)
A Multicenter, Randomized, Sham-control, Proof-of-concept Study of Intravitreal LFG316 in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)
A Multicenter, Randomized, Sham-control, Proof-of-concept Study of Intravitreal LFG316 in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Fort Myers, FL
Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)
A Multicenter, Randomized, Sham-control, Proof-of-concept Study of Intravitreal LFG316 in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)
A Multicenter, Randomized, Sham-control, Proof-of-concept Study of Intravitreal LFG316 in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Silverdale, WA
Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)
A Multicenter, Randomized, Sham-control, Proof-of-concept Study of Intravitreal LFG316 in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Silverdale, WA
Click here to add this to my saved trials
Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)
A Multicenter, Randomized, Sham-control, Proof-of-concept Study of Intravitreal LFG316 in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Winter Haven, FL
Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)
A Multicenter, Randomized, Sham-control, Proof-of-concept Study of Intravitreal LFG316 in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Winter Haven, FL
Click here to add this to my saved trials
Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)
A Multicenter, Randomized, Sham-control, Proof-of-concept Study of Intravitreal LFG316 in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Atlanta, GA
Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)
A Multicenter, Randomized, Sham-control, Proof-of-concept Study of Intravitreal LFG316 in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)
A Multicenter, Randomized, Sham-control, Proof-of-concept Study of Intravitreal LFG316 in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Leawood, KA
Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)
A Multicenter, Randomized, Sham-control, Proof-of-concept Study of Intravitreal LFG316 in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Leawood, KA
Click here to add this to my saved trials
Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)
A Multicenter, Randomized, Sham-control, Proof-of-concept Study of Intravitreal LFG316 in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative site
mi
from
Boston, MA
Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)
A Multicenter, Randomized, Sham-control, Proof-of-concept Study of Intravitreal LFG316 in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative site
mi
from
Boston, MA
Click here to add this to my saved trials
Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)
A Multicenter, Randomized, Sham-control, Proof-of-concept Study of Intravitreal LFG316 in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Grand Rapids, MI
Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)
A Multicenter, Randomized, Sham-control, Proof-of-concept Study of Intravitreal LFG316 in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)
A Multicenter, Randomized, Sham-control, Proof-of-concept Study of Intravitreal LFG316 in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Jackson, MI
Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)
A Multicenter, Randomized, Sham-control, Proof-of-concept Study of Intravitreal LFG316 in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Jackson, MI
Click here to add this to my saved trials
Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)
A Multicenter, Randomized, Sham-control, Proof-of-concept Study of Intravitreal LFG316 in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Charlotte, NC
Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)
A Multicenter, Randomized, Sham-control, Proof-of-concept Study of Intravitreal LFG316 in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Charlotte, NC
Click here to add this to my saved trials
Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)
A Multicenter, Randomized, Sham-control, Proof-of-concept Study of Intravitreal LFG316 in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Cincinnati, OH
Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)
A Multicenter, Randomized, Sham-control, Proof-of-concept Study of Intravitreal LFG316 in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)
A Multicenter, Randomized, Sham-control, Proof-of-concept Study of Intravitreal LFG316 in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Phoenix, AZ
Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)
A Multicenter, Randomized, Sham-control, Proof-of-concept Study of Intravitreal LFG316 in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)
A Multicenter, Randomized, Sham-control, Proof-of-concept Study of Intravitreal LFG316 in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Tucson, AZ
Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)
A Multicenter, Randomized, Sham-control, Proof-of-concept Study of Intravitreal LFG316 in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Tucson, AZ
Click here to add this to my saved trials
Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)
A Multicenter, Randomized, Sham-control, Proof-of-concept Study of Intravitreal LFG316 in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Cleveland, OH
Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)
A Multicenter, Randomized, Sham-control, Proof-of-concept Study of Intravitreal LFG316 in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Cleveland, OH
Click here to add this to my saved trials
Retinal Imaging of Subjects Implanted With Ciliary Neurotrophic Factor (CNTF)-Releasing Encapsulated Cell Implant for Early-stage Retinitis Pigmentosa
Photoreceptor Structure in A Phase 2 Study of Encapsulated Human NTC-201 Cell Implants Releasing Ciliary Neurotrophic Factor (CNTF) for Participants With Retinitis Pigmentosa Using Rates of Change in Cone Spacing and Density
Status: Enrolling
Updated:  12/31/1969
University of California at San Francisco
mi
from
San Francisco, CA
Retinal Imaging of Subjects Implanted With Ciliary Neurotrophic Factor (CNTF)-Releasing Encapsulated Cell Implant for Early-stage Retinitis Pigmentosa
Photoreceptor Structure in A Phase 2 Study of Encapsulated Human NTC-201 Cell Implants Releasing Ciliary Neurotrophic Factor (CNTF) for Participants With Retinitis Pigmentosa Using Rates of Change in Cone Spacing and Density
Status: Enrolling
Updated: 12/31/1969
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Rapid, Non-invasive, Regional Functional Imaging of the Retina. (Diabetic Retinopathy Diagnosis Device)
Developing a Non-invasive Method and Device for Assessing the Degree of Midperipheral Retinal Ischemia in Diabetic Retinopathy.
Status: Enrolling
Updated:  12/31/1969
Jules Stein Eye Institute, Dept. of Ophthalmology David Geffen School of Medicine at UCLA
mi
from
Los Angeles, CA
Rapid, Non-invasive, Regional Functional Imaging of the Retina. (Diabetic Retinopathy Diagnosis Device)
Developing a Non-invasive Method and Device for Assessing the Degree of Midperipheral Retinal Ischemia in Diabetic Retinopathy.
Status: Enrolling
Updated: 12/31/1969
Jules Stein Eye Institute, Dept. of Ophthalmology David Geffen School of Medicine at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Rapid, Non-invasive, Regional Functional Imaging of the Retina. (Diabetic Retinopathy Diagnosis Device)
Developing a Non-invasive Method and Device for Assessing the Degree of Midperipheral Retinal Ischemia in Diabetic Retinopathy.
Status: Enrolling
Updated:  12/31/1969
Neuro Kinetics Inc.
mi
from
Pittsburgh, PA
Rapid, Non-invasive, Regional Functional Imaging of the Retina. (Diabetic Retinopathy Diagnosis Device)
Developing a Non-invasive Method and Device for Assessing the Degree of Midperipheral Retinal Ischemia in Diabetic Retinopathy.
Status: Enrolling
Updated: 12/31/1969
Neuro Kinetics Inc.
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Shunt Tube Exposure Prevention Study
Amniotic Membrane Versus Pericardium in Reducing Glaucoma Drainage Tube Exposure: A Randomized Clinical Trial
Status: Enrolling
Updated:  12/31/1969
Bascom Palmer Eye Institute
mi
from
Miami, FL
Shunt Tube Exposure Prevention Study
Amniotic Membrane Versus Pericardium in Reducing Glaucoma Drainage Tube Exposure: A Randomized Clinical Trial
Status: Enrolling
Updated: 12/31/1969
Bascom Palmer Eye Institute
mi
from
Miami, FL
Click here to add this to my saved trials
Shunt Tube Exposure Prevention Study
Amniotic Membrane Versus Pericardium in Reducing Glaucoma Drainage Tube Exposure: A Randomized Clinical Trial
Status: Enrolling
Updated:  12/31/1969
New York Eye & Ear Infirmary
mi
from
New York, NY
Shunt Tube Exposure Prevention Study
Amniotic Membrane Versus Pericardium in Reducing Glaucoma Drainage Tube Exposure: A Randomized Clinical Trial
Status: Enrolling
Updated: 12/31/1969
New York Eye & Ear Infirmary
mi
from
New York, NY
Click here to add this to my saved trials
Shunt Tube Exposure Prevention Study
Amniotic Membrane Versus Pericardium in Reducing Glaucoma Drainage Tube Exposure: A Randomized Clinical Trial
Status: Enrolling
Updated:  12/31/1969
Manhattan Eye, Ear & Throat Hospital
mi
from
New York, NY
Shunt Tube Exposure Prevention Study
Amniotic Membrane Versus Pericardium in Reducing Glaucoma Drainage Tube Exposure: A Randomized Clinical Trial
Status: Enrolling
Updated: 12/31/1969
Manhattan Eye, Ear & Throat Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Shunt Tube Exposure Prevention Study
Amniotic Membrane Versus Pericardium in Reducing Glaucoma Drainage Tube Exposure: A Randomized Clinical Trial
Status: Enrolling
Updated:  12/31/1969
Harkness Eye Institute/ Columbia University
mi
from
New York, NY
Shunt Tube Exposure Prevention Study
Amniotic Membrane Versus Pericardium in Reducing Glaucoma Drainage Tube Exposure: A Randomized Clinical Trial
Status: Enrolling
Updated: 12/31/1969
Harkness Eye Institute/ Columbia University
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE)
A Phase I/II, Randomized, Study for Diabetic Macular Edema Using 0.3mg Ranibizumab Combined With Targeted PRP Monthly for 4 Months,Then PRN vs. 0.3mg Ranibizumab 4 Months Monotherapy, Then as Needed(DME-AntiVEgf) DAVE
Status: Enrolling
Updated:  12/31/1969
Retina Consultants of Houston
mi
from
Houston, TX
Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE)
A Phase I/II, Randomized, Study for Diabetic Macular Edema Using 0.3mg Ranibizumab Combined With Targeted PRP Monthly for 4 Months,Then PRN vs. 0.3mg Ranibizumab 4 Months Monotherapy, Then as Needed(DME-AntiVEgf) DAVE
Status: Enrolling
Updated: 12/31/1969
Retina Consultants of Houston
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE)
A Phase I/II, Randomized, Study for Diabetic Macular Edema Using 0.3mg Ranibizumab Combined With Targeted PRP Monthly for 4 Months,Then PRN vs. 0.3mg Ranibizumab 4 Months Monotherapy, Then as Needed(DME-AntiVEgf) DAVE
Status: Enrolling
Updated:  12/31/1969
Retina Consultants of Houston
mi
from
Katy, TX
Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE)
A Phase I/II, Randomized, Study for Diabetic Macular Edema Using 0.3mg Ranibizumab Combined With Targeted PRP Monthly for 4 Months,Then PRN vs. 0.3mg Ranibizumab 4 Months Monotherapy, Then as Needed(DME-AntiVEgf) DAVE
Status: Enrolling
Updated: 12/31/1969
Retina Consultants of Houston
mi
from
Katy, TX
Click here to add this to my saved trials
Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE)
A Phase I/II, Randomized, Study for Diabetic Macular Edema Using 0.3mg Ranibizumab Combined With Targeted PRP Monthly for 4 Months,Then PRN vs. 0.3mg Ranibizumab 4 Months Monotherapy, Then as Needed(DME-AntiVEgf) DAVE
Status: Enrolling
Updated:  12/31/1969
Retina Consultants of Houston
mi
from
The Woodlands, TX
Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE)
A Phase I/II, Randomized, Study for Diabetic Macular Edema Using 0.3mg Ranibizumab Combined With Targeted PRP Monthly for 4 Months,Then PRN vs. 0.3mg Ranibizumab 4 Months Monotherapy, Then as Needed(DME-AntiVEgf) DAVE
Status: Enrolling
Updated: 12/31/1969
Retina Consultants of Houston
mi
from
The Woodlands, TX
Click here to add this to my saved trials
Continuation of Previous Study to Gather More Data on Effect of Macugen on the Corneal Endothelium
A Phase IV, Open Label, Multi-center Study to Assess the Effect of Intravitreal Injections of Macugen (Pegaptanib Sodium Injection)Administered Every 6 Weeks for 48 Weeks on the Corneal Endothelium.
Status: Enrolling
Updated:  12/31/1969
Wolfe Eye Clinic
mi
from
Marshalltown, IA
Continuation of Previous Study to Gather More Data on Effect of Macugen on the Corneal Endothelium
A Phase IV, Open Label, Multi-center Study to Assess the Effect of Intravitreal Injections of Macugen (Pegaptanib Sodium Injection)Administered Every 6 Weeks for 48 Weeks on the Corneal Endothelium.
Status: Enrolling
Updated: 12/31/1969
Wolfe Eye Clinic
mi
from
Marshalltown, IA
Click here to add this to my saved trials
Continuation of Previous Study to Gather More Data on Effect of Macugen on the Corneal Endothelium
A Phase IV, Open Label, Multi-center Study to Assess the Effect of Intravitreal Injections of Macugen (Pegaptanib Sodium Injection)Administered Every 6 Weeks for 48 Weeks on the Corneal Endothelium.
Status: Enrolling
Updated:  12/31/1969
Associates in Ophthalmology
mi
from
West Mifflin, PA
Continuation of Previous Study to Gather More Data on Effect of Macugen on the Corneal Endothelium
A Phase IV, Open Label, Multi-center Study to Assess the Effect of Intravitreal Injections of Macugen (Pegaptanib Sodium Injection)Administered Every 6 Weeks for 48 Weeks on the Corneal Endothelium.
Status: Enrolling
Updated: 12/31/1969
Associates in Ophthalmology
mi
from
West Mifflin, PA
Click here to add this to my saved trials
Continuation of Previous Study to Gather More Data on Effect of Macugen on the Corneal Endothelium
A Phase IV, Open Label, Multi-center Study to Assess the Effect of Intravitreal Injections of Macugen (Pegaptanib Sodium Injection)Administered Every 6 Weeks for 48 Weeks on the Corneal Endothelium.
Status: Enrolling
Updated:  12/31/1969
Valley Retina Institute
mi
from
Harlingen, TX
Continuation of Previous Study to Gather More Data on Effect of Macugen on the Corneal Endothelium
A Phase IV, Open Label, Multi-center Study to Assess the Effect of Intravitreal Injections of Macugen (Pegaptanib Sodium Injection)Administered Every 6 Weeks for 48 Weeks on the Corneal Endothelium.
Status: Enrolling
Updated: 12/31/1969
Valley Retina Institute
mi
from
Harlingen, TX
Click here to add this to my saved trials
Continuation of Previous Study to Gather More Data on Effect of Macugen on the Corneal Endothelium
A Phase IV, Open Label, Multi-center Study to Assess the Effect of Intravitreal Injections of Macugen (Pegaptanib Sodium Injection)Administered Every 6 Weeks for 48 Weeks on the Corneal Endothelium.
Status: Enrolling
Updated:  12/31/1969
Marietta Eye Clinic
mi
from
Murrieta, CA
Continuation of Previous Study to Gather More Data on Effect of Macugen on the Corneal Endothelium
A Phase IV, Open Label, Multi-center Study to Assess the Effect of Intravitreal Injections of Macugen (Pegaptanib Sodium Injection)Administered Every 6 Weeks for 48 Weeks on the Corneal Endothelium.
Status: Enrolling
Updated: 12/31/1969
Marietta Eye Clinic
mi
from
Murrieta, CA
Click here to add this to my saved trials
Intra-arterial Thrombolysis for Severe Recent Central Retinal Vein Occlusion
Phase 1 Trial of Intra-Ophthalmic Artery Thrombolysis for Treating Recent Severe Central Retinal Vein Occlusion
Status: Enrolling
Updated:  12/31/1969
Weill Cornell Medical College/New York Presbyterian Hospital
mi
from
New York, NY
Intra-arterial Thrombolysis for Severe Recent Central Retinal Vein Occlusion
Phase 1 Trial of Intra-Ophthalmic Artery Thrombolysis for Treating Recent Severe Central Retinal Vein Occlusion
Status: Enrolling
Updated: 12/31/1969
Weill Cornell Medical College/New York Presbyterian Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Intraoperative OCT Guidance of Intraocular Surgery
Intraoperative OCT Guidance of Intraocular Surgery
Status: Enrolling
Updated:  12/31/1969
Duke University Eye Center
mi
from
Durham, NC
Intraoperative OCT Guidance of Intraocular Surgery
Intraoperative OCT Guidance of Intraocular Surgery
Status: Enrolling
Updated: 12/31/1969
Duke University Eye Center
mi
from
Durham, NC
Click here to add this to my saved trials
Intraoperative OCT Guidance of Intraocular Surgery
Intraoperative OCT Guidance of Intraocular Surgery
Status: Enrolling
Updated:  12/31/1969
Cole Eye Institute at the Cleveland Clinic Lemer College of Medicine
mi
from
Cleveland, OH
Intraoperative OCT Guidance of Intraocular Surgery
Intraoperative OCT Guidance of Intraocular Surgery
Status: Enrolling
Updated: 12/31/1969
Cole Eye Institute at the Cleveland Clinic Lemer College of Medicine
mi
from
Cleveland, OH
Click here to add this to my saved trials
Post Photorefractive Keratectomy (PRK) Use of an Eye Shield for Maintaining Vision and Mitigating Pain
Post Photorefractive Keratectomy (PRK) Use of an Eye Shield for Maintaining Vision and Mitigating Pain
Status: Enrolling
Updated:  12/31/1969
Byers Eye Institute at Stanford
mi
from
Palo Alto, CA
Post Photorefractive Keratectomy (PRK) Use of an Eye Shield for Maintaining Vision and Mitigating Pain
Post Photorefractive Keratectomy (PRK) Use of an Eye Shield for Maintaining Vision and Mitigating Pain
Status: Enrolling
Updated: 12/31/1969
Byers Eye Institute at Stanford
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Delivery Prior to Implantation of a Posterior Chamber IOL
A Prospective, Multi-Center, Randomized, Double-Masked, Negative-Controlled Clinical Trial Designed to Compare the Safety and Efficacy of EGP-437 (Dexamethasone Phosphate Ophthalmic Solution) Delivered by EyeGate® II Iontophoresis to Placebo in Patients Undergoing Cataract Surgery With Implantation of a Posterior Chamber Intraocular Lens
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Miami, FL
Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Delivery Prior to Implantation of a Posterior Chamber IOL
A Prospective, Multi-Center, Randomized, Double-Masked, Negative-Controlled Clinical Trial Designed to Compare the Safety and Efficacy of EGP-437 (Dexamethasone Phosphate Ophthalmic Solution) Delivered by EyeGate® II Iontophoresis to Placebo in Patients Undergoing Cataract Surgery With Implantation of a Posterior Chamber Intraocular Lens
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Delivery Prior to Implantation of a Posterior Chamber IOL
A Prospective, Multi-Center, Randomized, Double-Masked, Negative-Controlled Clinical Trial Designed to Compare the Safety and Efficacy of EGP-437 (Dexamethasone Phosphate Ophthalmic Solution) Delivered by EyeGate® II Iontophoresis to Placebo in Patients Undergoing Cataract Surgery With Implantation of a Posterior Chamber Intraocular Lens
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Tamarac, FL
Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Delivery Prior to Implantation of a Posterior Chamber IOL
A Prospective, Multi-Center, Randomized, Double-Masked, Negative-Controlled Clinical Trial Designed to Compare the Safety and Efficacy of EGP-437 (Dexamethasone Phosphate Ophthalmic Solution) Delivered by EyeGate® II Iontophoresis to Placebo in Patients Undergoing Cataract Surgery With Implantation of a Posterior Chamber Intraocular Lens
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Tamarac, FL
Click here to add this to my saved trials
Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Delivery Prior to Implantation of a Posterior Chamber IOL
A Prospective, Multi-Center, Randomized, Double-Masked, Negative-Controlled Clinical Trial Designed to Compare the Safety and Efficacy of EGP-437 (Dexamethasone Phosphate Ophthalmic Solution) Delivered by EyeGate® II Iontophoresis to Placebo in Patients Undergoing Cataract Surgery With Implantation of a Posterior Chamber Intraocular Lens
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Washington, MO
Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Delivery Prior to Implantation of a Posterior Chamber IOL
A Prospective, Multi-Center, Randomized, Double-Masked, Negative-Controlled Clinical Trial Designed to Compare the Safety and Efficacy of EGP-437 (Dexamethasone Phosphate Ophthalmic Solution) Delivered by EyeGate® II Iontophoresis to Placebo in Patients Undergoing Cataract Surgery With Implantation of a Posterior Chamber Intraocular Lens
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Washington, MO
Click here to add this to my saved trials
Tocilizumab in the Management of Juvenile Idiopathic Arthritis Associated Uveitis
An Open-label Trial to Assess the Efficacy and Safety of Tocilizumab in the Management of Juvenile Idiopathic Arthritis Associated Vision-threatening Uveitis That is Refractory to Other Modes of Systemic Immunosuppression
Status: Enrolling
Updated:  12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Tocilizumab in the Management of Juvenile Idiopathic Arthritis Associated Uveitis
An Open-label Trial to Assess the Efficacy and Safety of Tocilizumab in the Management of Juvenile Idiopathic Arthritis Associated Vision-threatening Uveitis That is Refractory to Other Modes of Systemic Immunosuppression
Status: Enrolling
Updated: 12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Ozurdex for Diabetic Macular Edema Treated With Pars Plana vitrEctomy and Membrane RemovAl (OPERA Study)
Ozurdex for Diabetic Macular Edema Treated With Pars Plana vitrEctomy and Membrane RemovAl (OPERA Study)
Status: Enrolling
Updated:  12/31/1969
Cole Eye Institute, Cleveland Clinic
mi
from
Cleveland, OH
Ozurdex for Diabetic Macular Edema Treated With Pars Plana vitrEctomy and Membrane RemovAl (OPERA Study)
Ozurdex for Diabetic Macular Edema Treated With Pars Plana vitrEctomy and Membrane RemovAl (OPERA Study)
Status: Enrolling
Updated: 12/31/1969
Cole Eye Institute, Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Wet Macular Degeneration Study to Compare Ranibizumab or Bevacizumab to Aflibercept
A Single Arm, Investigator Initiated Study of the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Injection in Subjects With Exudative Age-related Macular Degeneration Previously Treated With Ranibizumab or Bevacizumab (ASSESS Study)
Status: Enrolling
Updated:  12/31/1969
Cole Eye Institute, Cleveland Clinic
mi
from
Cleveland, OH
Wet Macular Degeneration Study to Compare Ranibizumab or Bevacizumab to Aflibercept
A Single Arm, Investigator Initiated Study of the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Injection in Subjects With Exudative Age-related Macular Degeneration Previously Treated With Ranibizumab or Bevacizumab (ASSESS Study)
Status: Enrolling
Updated: 12/31/1969
Cole Eye Institute, Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Use of the VisuMax™ Femtosecond Laser
Use of the VisuMax™ Femtosecond Laser Lenticule Removal Procedure for the Correction of Myopia
Status: Enrolling
Updated:  12/31/1969
Dishler Laser Institute
mi
from
Greenwood Village, CO
Use of the VisuMax™ Femtosecond Laser
Use of the VisuMax™ Femtosecond Laser Lenticule Removal Procedure for the Correction of Myopia
Status: Enrolling
Updated: 12/31/1969
Dishler Laser Institute
mi
from
Greenwood Village, CO
Click here to add this to my saved trials
Use of the VisuMax™ Femtosecond Laser
Use of the VisuMax™ Femtosecond Laser Lenticule Removal Procedure for the Correction of Myopia
Status: Enrolling
Updated:  12/31/1969
Bascom Palmer Eye Institute
mi
from
Miami, FL
Use of the VisuMax™ Femtosecond Laser
Use of the VisuMax™ Femtosecond Laser Lenticule Removal Procedure for the Correction of Myopia
Status: Enrolling
Updated: 12/31/1969
Bascom Palmer Eye Institute
mi
from
Miami, FL
Click here to add this to my saved trials
Use of the VisuMax™ Femtosecond Laser
Use of the VisuMax™ Femtosecond Laser Lenticule Removal Procedure for the Correction of Myopia
Status: Enrolling
Updated:  12/31/1969
Discover Vision Centers
mi
from
Leawood, KA
Use of the VisuMax™ Femtosecond Laser
Use of the VisuMax™ Femtosecond Laser Lenticule Removal Procedure for the Correction of Myopia
Status: Enrolling
Updated: 12/31/1969
Discover Vision Centers
mi
from
Leawood, KA
Click here to add this to my saved trials
Use of the VisuMax™ Femtosecond Laser
Use of the VisuMax™ Femtosecond Laser Lenticule Removal Procedure for the Correction of Myopia
Status: Enrolling
Updated:  12/31/1969
Vance Thompson Vision
mi
from
Sioux Falls, SD
Use of the VisuMax™ Femtosecond Laser
Use of the VisuMax™ Femtosecond Laser Lenticule Removal Procedure for the Correction of Myopia
Status: Enrolling
Updated: 12/31/1969
Vance Thompson Vision
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Use of the VisuMax™ Femtosecond Laser
Use of the VisuMax™ Femtosecond Laser Lenticule Removal Procedure for the Correction of Myopia
Status: Enrolling
Updated:  12/31/1969
Davis Duehr Dean
mi
from
Madison, WI
Use of the VisuMax™ Femtosecond Laser
Use of the VisuMax™ Femtosecond Laser Lenticule Removal Procedure for the Correction of Myopia
Status: Enrolling
Updated: 12/31/1969
Davis Duehr Dean
mi
from
Madison, WI
Click here to add this to my saved trials
Safety Study of Lifitegrast to Treat Dry Eye
A Phase 3, Multicenter, Randomized, Double-Masked and Placebo-Controlled Study Evaluating the Safety of a 5.0% Concentration of Lifitegrast Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (SONATA)
Status: Enrolling
Updated:  12/31/1969
SONATA Investigational Site
mi
from
Artesia, CA
Safety Study of Lifitegrast to Treat Dry Eye
A Phase 3, Multicenter, Randomized, Double-Masked and Placebo-Controlled Study Evaluating the Safety of a 5.0% Concentration of Lifitegrast Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (SONATA)
Status: Enrolling
Updated: 12/31/1969
SONATA Investigational Site
mi
from
Artesia, CA
Click here to add this to my saved trials
Safety Study of Lifitegrast to Treat Dry Eye
A Phase 3, Multicenter, Randomized, Double-Masked and Placebo-Controlled Study Evaluating the Safety of a 5.0% Concentration of Lifitegrast Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (SONATA)
Status: Enrolling
Updated:  12/31/1969
SONATA Investigational Site
mi
from
Parker, CO
Safety Study of Lifitegrast to Treat Dry Eye
A Phase 3, Multicenter, Randomized, Double-Masked and Placebo-Controlled Study Evaluating the Safety of a 5.0% Concentration of Lifitegrast Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (SONATA)
Status: Enrolling
Updated: 12/31/1969
SONATA Investigational Site
mi
from
Parker, CO
Click here to add this to my saved trials
Safety Study of Lifitegrast to Treat Dry Eye
A Phase 3, Multicenter, Randomized, Double-Masked and Placebo-Controlled Study Evaluating the Safety of a 5.0% Concentration of Lifitegrast Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (SONATA)
Status: Enrolling
Updated:  12/31/1969
SONATA Investigational Site
mi
from
Boynton Beach, FL
Safety Study of Lifitegrast to Treat Dry Eye
A Phase 3, Multicenter, Randomized, Double-Masked and Placebo-Controlled Study Evaluating the Safety of a 5.0% Concentration of Lifitegrast Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (SONATA)
Status: Enrolling
Updated: 12/31/1969
SONATA Investigational Site
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
Safety Study of Lifitegrast to Treat Dry Eye
A Phase 3, Multicenter, Randomized, Double-Masked and Placebo-Controlled Study Evaluating the Safety of a 5.0% Concentration of Lifitegrast Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (SONATA)
Status: Enrolling
Updated:  12/31/1969
SONATA Investigational Site
mi
from
Roswell, GA
Safety Study of Lifitegrast to Treat Dry Eye
A Phase 3, Multicenter, Randomized, Double-Masked and Placebo-Controlled Study Evaluating the Safety of a 5.0% Concentration of Lifitegrast Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (SONATA)
Status: Enrolling
Updated: 12/31/1969
SONATA Investigational Site
mi
from
Roswell, GA
Click here to add this to my saved trials
Safety Study of Lifitegrast to Treat Dry Eye
A Phase 3, Multicenter, Randomized, Double-Masked and Placebo-Controlled Study Evaluating the Safety of a 5.0% Concentration of Lifitegrast Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (SONATA)
Status: Enrolling
Updated:  12/31/1969
SONATA Investigational Site
mi
from
Hoffman Estates, IL
Safety Study of Lifitegrast to Treat Dry Eye
A Phase 3, Multicenter, Randomized, Double-Masked and Placebo-Controlled Study Evaluating the Safety of a 5.0% Concentration of Lifitegrast Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (SONATA)
Status: Enrolling
Updated: 12/31/1969
SONATA Investigational Site
mi
from
Hoffman Estates, IL
Click here to add this to my saved trials
Safety Study of Lifitegrast to Treat Dry Eye
A Phase 3, Multicenter, Randomized, Double-Masked and Placebo-Controlled Study Evaluating the Safety of a 5.0% Concentration of Lifitegrast Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (SONATA)
Status: Enrolling
Updated:  12/31/1969
SONATA Investigational Site
mi
from
Edgewood, KY
Safety Study of Lifitegrast to Treat Dry Eye
A Phase 3, Multicenter, Randomized, Double-Masked and Placebo-Controlled Study Evaluating the Safety of a 5.0% Concentration of Lifitegrast Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (SONATA)
Status: Enrolling
Updated: 12/31/1969
SONATA Investigational Site
mi
from
Edgewood, KY
Click here to add this to my saved trials